| Literature DB >> 24031549 |
Rejane-Maria Tomasini-Grotto1, Brigitte Montes, Denise Triglia, Carla Torres-Braconi, Juliana Aliano-Block, Paolo M de A Zanotto, Maria-Inès de M C Pardini, Michel Segondy.
Abstract
The diversity of the V3 loop tip motif sequences of HIV-1 subtype B was analyzed in patients from Botucatu (Brazil) and Montpellier (France). Overall, 37 tetrameric tip motifs were identified, 28 and 17 of them being recognized in Brazilian and French patients, respectively. The GPGR (P) motif was predominant in French but not in Brazilian patients (53.5% vs 31.0%), whereas the GWGR (W) motif was frequent in Brazilian patients (23.0%) and absent in French patients. Three tip motif groups were considered: P, W, and non-P non-W groups. The distribution of HIV-1 isolates into the three groups was significantly different between isolates from Botucatu and from Montpellier (P < 0.001). A higher proportion of CXCR4-using HIV-1 (X4 variants) was observed in the non-P non-W group as compared with the P group (37.5% vs 19.1%), and no X4 variant was identified in the W group (P < 0.001). The higher proportion of X4 variants in the non-P non-W group was essentially observed among the patients from Montpellier, who have been infected with HIV-1 for a longer period of time than those from Botucatu. Among patients from Montpellier, CD4+ cell counts were lower in patients belonging to the non-P non-W group than in those belonging to the P group (24 cells/μL vs 197 cells/μL; P = 0.005). Taken together, the results suggest that variability of the V3 loop tip motif may be related to HIV-1 coreceptor usage and to disease progression. However, as analyzed by a bioinformatic method, the substitution of the V3 loop tip motif of the subtype B consensus sequence with the different tip motifs identified in the present study was not sufficient to induce a change in HIV-1 coreceptor usage.Entities:
Keywords: Brazil; France; Genetic diversity; HIV-1; V3 loop
Year: 2010 PMID: 24031549 PMCID: PMC3768648 DOI: 10.1590/S1517-83822010000300024
Source DB: PubMed Journal: Braz J Microbiol ISSN: 1517-8382 Impact factor: 2.476
Demographic, virological, immunological and clinical characteristics of HIV-1 subtype B-infected patients from Botucatu and Montpellier.
| Age, y [median (IQR)] | 39 (34-46) | 44 (40-50) | <0.001 |
| Sex, Male [N (%)] | 51 (51.0) | 73 (84.9) | <0.001 |
| HIV-1 risk factors [N (%)] | <0.001 | ||
| Heterosexual | 24 (24.0) | 11 (12.8) | |
| MSM | 26 (26.0) | 63 (73.2) | |
| IDU | 17 (17.0) | 6 (7.0) | |
| Transfusion/hemophilia | 6 (6.0) | 4 (4.7) | |
| Unknown | 27 (27.0) | 2 (2.3) | |
| Treatment [N (%)] | 0.005 | ||
| Naive | 9 (9.0) | 14 (16.3) | |
| Discontinuation | 6 (6.0) | 14 (16.3) | |
| On treatment | 85 (85.0) | 58 (67.4) | |
| Duration of HIV-1 infection, y [median (IQR)] | 6 (2-9) | 11 [8-15] | <0.001 |
| CDC stage B or C, [N (%)] | 47 (47.0) | 64 (74.4) | <0.001 |
| CD4+ cell count, cells/μL [median (IQR)] | 332 (189-455) | 186 (58-307) | <0.001 |
| Viral load, log copies/mL [median (IQR)] | 2.73 (1.70-4.14) | 4.65 (4.23-5.21) | <0.001 |
Tip motif distribution in HIV-1 subtype B isolates from Botucatu and Montpellier.
| P | 44 (44.0%) | 71 (82.6%) |
| GPGR | 31 | 46 |
| GPGK | 5 | 11 |
| GPGS | 1 | 8 |
| GPGQ | 4 | 3 |
| GPGG | 3 | 3 |
| W | 23 (23.0%) | 0 (0.0%) |
| GWGR | ||
| Non-P non-W | 33 (33.0%) | 15 (17.4%) |
| AGGR | 1 | 0 |
| AKGR | 1 | 0 |
| AMGR | 1 | 0 |
| APAG | 1 | 0 |
| APGK | 2 | 0 |
| APGR | 3 | 4 |
| APGS | 0 | 1 |
| AWGR | 1 | 0 |
| GAGR | 2 | 0 |
| GFGR | 4 | 0 |
| GGGR | 2 | 0 |
| GIRK | 0 | 1 |
| GIRR | 0 | 1 |
| GLGQ | 0 | 1 |
| GLGR | 2 | 1 |
| GLRK | 0 | 1 |
| GMGR | 1 | 0 |
| GPKR | 1 | 0 |
| GRGR | 1 | 0 |
| GSGR | 0 | 1 |
| GTGR | 1 | 0 |
| GWKR | 1 | 0 |
| GWRR | 2 | 1 |
| HPGK | 0 | 1 |
| HPGR | 0 | 1 |
| QPGR | 0 | 1 |
| RPGS | 1 | 0 |
| RPRR | 1 | 0 |
| RWGR | 1 | 0 |
| RWGT | 2 | 0 |
| SPGS | 1 | 0 |
Relationships between tip motif groups and demographic, virological, immunological and clinical characteristics of patients infected with HIV-1 subtype B.
| Age, y [median (IQR)] | 43 (38-50) | 35 (31-41) | 40 (28-45) | 0.005 |
| Sex, Male [N (%)] | 85 (73.9) | 9 (39.1) | 30 (62.5) | 0.004 |
| HIV risk group [N (%)] | 0.02 | |||
| Heterosexual | 19 (16.5) | 6 (26.1) | 10 (20.8) | |
| MSM | 65 (56.5) | 4 (17.4) | 20 (41.7) | |
| IDU | 8 (7.0) | 7 (30.4) | 8 (16.7) | |
| Transfusion/hemophilia | 7 (6.1) | 1 (4.4) | 2 (4.2) | |
| Unknown | 16 (13.9) | 5 (21.7) | 8 (16.7) | |
| Treatment [N (%)] | 0.66 | |||
| Naive | 17 (14.8) | 3 (13.0) | 3 (6.3) | |
| Discontinuation | 12 (10.4) | 2 (8.7) | 6 (12.5) | |
| On treatment | 86 (74.8) | 18 (78.3) | 39 (81.2) | |
| Duration of HIV-1 infection, y [median (IQR)] | 9.0 (5.0-13) | 4.0 (2.0-7.0) | 9.0 (3.5-11.0) 9.0 | lt;0.001 |
| CDC stage B or C [N (%)] | 71 (61.7) | 10 (43.5) | 30 (62.5) | 0.24 |
| HIV-1 X4 variant [N (%)] | 22 (19.1) | 0 (0.0) | 18 (37.5) | <0.001 |
| CD4+ cell count, cells/�L [median (IQR)] | 246 (125-381) | 378 (237-540) | 248 (89-418) | 0.19 |
| Viral load, log copies/mL [median (IQR)] | 4.26 (3.26-4.95) | 2.68 (1.70-4.31) | 3.71 (1.74-4.50) | 0.003 |
Relationships between tip motif groups and demographic, virological, immunological and clinical characteristics among HIV-1 subtype B-infected patients from Botucatu and Montpellier.
| Age, y, [ median (IQR)] | 39.5 (36.5-48.5) | 35.0 (31.0-41.0) | 38.5 34.5-44.0) | 0.09 | 44.0 (39.0-50.0) | 44.0 (41.0-53.0) | 0.59 |
| Sex, Male [N (%)] | 27 (61.4) | 9 (39.1) | 15 (45.5) | 0.17 | 58 (81.7) | 15 (100) | 0.11 |
| HIV-1 risk factors [N (%)] | 0.44 | 0.69 | |||||
| Heterosexual | 9 (20.5) | 6 (26.1) | 9 (27.3) | 10 (14.1) | 1 (6.7) | ||
| MSM | 15 (34.1) | 4 (17.4) | 7 (21.2) | 50 (70.4) | 13 (86.7) | ||
| IDU | 3 (6.8) | 7 (30.4) | 7 (21.2) | 5 (7.0) | 1 (6.7) | ||
| Transfusion/hemophilia | 3 (6.8) | 1 (4.4) | 2 (6.1) | 4 (5.6) | 0 (0) | ||
| Unknown | 14 (31.8) | 5 (21.7) | 8 (24.2) | 2 (2.8) | 0 (0) | ||
| Treatment [N (%)] | 0.60 | 0.53 | |||||
| Naive | 4 (9.1) | 3 (13.0) | 2 (6.1) | 13 (18.3) | 1 (6.7) | ||
| Discontinuation | 1 (2.3) | 2 (8.7) | 3 (9.1) | 11 (15.5) | 3 (20.0) | ||
| On treatment | 39 (88.6) | 18 (78.3) | 28 (84.8) | 47 (66.2) | 11 (73.3) | ||
| Duration of HIV-1 infection, y[median (IQR)] | 6.0(3.5-9.5) | 4.0(2.0-7.0) | 6.0(2.0-10.0) | 0.16 | 11 .0(8.0-16.0) | 10.0(9.0-13.0) | 0.78 |
| CDC stage B or C [N (%)] | 19 (43.2) | 10 (43.5) | 18 (54.5) | 0.57 | 52 (73.2) | 12 (80.0) | 0.75 |
| HIV-1 X4 variant [N (%)] | 9 (20.4) | 0 (0.0) | 10 (30.3) | 0.02 | 13 (18.3) | 8 (53.3) | 0.007 |
| CD4+ cell count, cells/μL[median (IQR)] | 312(213-455) | 378237-540) | 323(173-451) | 0.95 | 197(89-332) | 24(7.0-233) | 0.005 |
| Viral load, log copies/mL[median (IQR)] | 3.23(1.70-4.23) | 2.68(1.7-4.31) | 2.48(1.70-3.99) | 0.88 | 2.73(1.70-4.14) | 3.04(1.70-4.46) | 0.60 |